163 related articles for article (PubMed ID: 12145162)
1. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection.
Abdi R; Smith RN; Makhlouf L; Najafian N; Luster AD; Auchincloss H; Sayegh MH
Diabetes; 2002 Aug; 51(8):2489-95. PubMed ID: 12145162
[TBL] [Abstract][Full Text] [Related]
2. Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo.
Abdi R; Means TK; Ito T; Smith RN; Najafian N; Jurewicz M; Tchipachvili V; Charo I; Auchincloss H; Sayegh MH; Luster AD
J Immunol; 2004 Jan; 172(2):767-75. PubMed ID: 14707046
[TBL] [Abstract][Full Text] [Related]
3. The role of chemokines and their receptors in the rejection of pig islet tissue xenografts.
Solomon MF; Kuziel WA; Mann DA; Simeonovic CJ
Xenotransplantation; 2003 Mar; 10(2):164-77. PubMed ID: 12588649
[TBL] [Abstract][Full Text] [Related]
4. The contribution of chemokines and chemokine receptors to the rejection of fetal proislet allografts.
Solomon MF; Kuziel WA; Simeonovic CJ
Cell Transplant; 2004; 13(5):503-14. PubMed ID: 15565863
[TBL] [Abstract][Full Text] [Related]
5. Chemokines in islet allograft rejection.
Abdi R; Means TK; Luster AD
Diabetes Metab Res Rev; 2003; 19(3):186-90. PubMed ID: 12789651
[TBL] [Abstract][Full Text] [Related]
6. Role of CXCR3 and CCR5 in allograft rejection.
Schnickel GT; Hsieh GR; Garcia C; Shefizadeh A; Fishbein MC; Ardehali A
Transplant Proc; 2006 Dec; 38(10):3221-4. PubMed ID: 17175228
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts.
Kohei N; Tanaka T; Tanabe K; Masumori N; Dvorina N; Valujskikh A; Baldwin WM; Fairchild RL
Kidney Int; 2016 Jun; 89(6):1293-306. PubMed ID: 27165816
[TBL] [Abstract][Full Text] [Related]
8. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection.
Akashi S; Sho M; Kashizuka H; Hamada K; Ikeda N; Kuzumoto Y; Tsurui Y; Nomi T; Mizuno T; Kanehiro H; Hisanaga M; Ko S; Nakajima Y
Transplantation; 2005 Aug; 80(3):378-84. PubMed ID: 16082334
[TBL] [Abstract][Full Text] [Related]
9. Permanent survival of fully MHC-mismatched islet allografts by targeting a single chemokine receptor pathway.
Wang L; Han R; Lee I; Hancock AS; Xiong G; Gunn MD; Hancock WW
J Immunol; 2005 Nov; 175(10):6311-8. PubMed ID: 16272282
[TBL] [Abstract][Full Text] [Related]
10. Blocking the CC chemokine receptor 5 pathway by antisense peptide nucleic acid prolongs islet allograft survival.
Yang L; Liu YF; Wu G; Zhang JL; Wang FS; Fu DZ; Zhao GH; Li TM
Transplant Proc; 2007; 39(1):185-90. PubMed ID: 17275502
[TBL] [Abstract][Full Text] [Related]
11. IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection.
Zhang Z; Kaptanoglu L; Tang Y; Ivancic D; Rao SM; Luster A; Barrett TA; Fryer J
Gastroenterology; 2004 Mar; 126(3):809-18. PubMed ID: 14988835
[TBL] [Abstract][Full Text] [Related]
12. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
[TBL] [Abstract][Full Text] [Related]
13. Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection.
Schnickel GT; Bastani S; Hsieh GR; Shefizadeh A; Bhatia R; Fishbein MC; Belperio J; Ardehali A
J Immunol; 2008 Apr; 180(7):4714-21. PubMed ID: 18354195
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the Th1/Th2 paradigm in transplantation: interferon-gamma deficiency converts Th1-type proislet allograft rejection to a Th2-type xenograft-like response.
Simeonovic CJ; Townsend MJ; Karupiah G; Wilson JD; Zarb JC; Mann DA; Young IG
Cell Transplant; 1999; 8(4):365-73. PubMed ID: 10478716
[TBL] [Abstract][Full Text] [Related]
15. Chemokine and toll-like receptor signaling in macrophage mediated islet xenograft rejection.
Chandra AP; Ouyang L; Yi S; Wong JK; Ha H; Walters SN; Patel AT; Stokes R; Jardine M; Hawthorne WJ; O'Connell PJ
Xenotransplantation; 2007 Jan; 14(1):48-59. PubMed ID: 17214704
[TBL] [Abstract][Full Text] [Related]
16. Expression of chemokines and chemokine receptors during human renal transplant rejection.
Segerer S; Cui Y; Eitner F; Goodpaster T; Hudkins KL; Mack M; Cartron JP; Colin Y; Schlondorff D; Alpers CE
Am J Kidney Dis; 2001 Mar; 37(3):518-31. PubMed ID: 11228176
[TBL] [Abstract][Full Text] [Related]
17. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long-term renal allograft outcome.
Dehmel S; Wang S; Schmidt C; Kiss E; Loewe RP; Chilla S; Schlöndorff D; Gröne HJ; Luckow B
Eur J Immunol; 2010 Jan; 40(1):267-78. PubMed ID: 19830734
[TBL] [Abstract][Full Text] [Related]
18. Islet allograft rejection can be mediated by CD4+, alloantigen experienced, direct pathway T cells of TH1 and TH2 cytokine phenotype.
Barbara JA; Turvey SE; Kingsley CI; Spriewald BM; Hara M; Witzke O; Morris PJ; Wood KJ
Transplantation; 2000 Dec; 70(11):1641-9. PubMed ID: 11152227
[TBL] [Abstract][Full Text] [Related]
19. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients.
Nozaki T; Amano H; Bickerstaff A; Orosz CG; Novick AC; Tanabe K; Fairchild RL
J Immunol; 2007 Oct; 179(8):5238-45. PubMed ID: 17911609
[TBL] [Abstract][Full Text] [Related]
20. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection.
Yun JJ; Whiting D; Fischbein MP; Banerji A; Irie Y; Stein D; Fishbein MC; Proudfoot AE; Laks H; Berliner JA; Ardehali A
Circulation; 2004 Feb; 109(7):932-7. PubMed ID: 14757698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
